Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New allergy shots show promise for dust mite sufferers

NCT ID NCT07427576

Disease control Sponsor: Inmunotek S.L. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a type of allergy immunotherapy (Clustoid® Max Forte) in 140 people aged 5 to 65 with dust mite allergies. The goal was to see if it reduces allergy and asthma symptoms and the need for medication over one year. Results were measured by symptom scores and medication use, and safety was monitored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

140 people

The number who actually took part.

Started

Mar 2025

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients aged 5 to 65 years with respiratory allergic diseases (allergic rhinitis/rhinoconjunctivitis with or without asthma) who have been treated or are being treated with Clustoid® Max Forte Dermatophagoides/Blomia tropicalis, with allergen code MM09/M608, for the two concentrations mentioned above.

Ages

5 to 65 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The study population consists of patients with respiratory allergic disease who are indicated for treatment with Clustoid® Max Forte immunotherapy according to standard clinical practice. 2. Age between 5 and 65 years, with no gender differences. 3. Who have received immunotherapy for at least one year. Exclusion Criteria: 1.Patients who have received immunotherapy with airborne allergens prior to the treatment to be evaluated in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

allergic disease allergic rhinitis asthma Dust Mite Allergy Rhinitis, Allergic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma Dermatophagoides farinae allergy Dermatophagoides pteronyssinus allergy Mite allergy Rhinitis allergic Rhinoconjunctivitis

Contacts and locations

Locations

  • Clínica Doctor García Robaina

    Santa Cruz de Tenerife, Canary Islands, 38002, Spain

  • Nuestra Señora de Candelaria

    Santa Cruz de Tenerife, Canary Islands, 38010, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.